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Abstract
Introduction: Associations of hormone-receptor positive breast cancer with excess adiposity are reasonably well
characterized; however, uncertainty remains regarding the association of body mass index (BMI) with hormone-
receptor negative malignancies, and possible interactions by hormone replacement therapy (HRT) use.
Methods: Within the European EPIC cohort, Cox proportional hazards models were used to describe the
relationship of BMI, waist and hip circumferences with risk of estrogen-receptor (ER) negative and progesterone-
receptor (PR) negative (n = 1,021) and ER+PR+ (n = 3,586) breast tumors within five-year age bands. Among
postmenopausal women, the joint effects of BMI and HRT use were analyzed.
Results: For risk of ER-PR- tumors, there was no association of BMI across the age bands. However, when analyses were
restricted to postmenopausal HRT never users, a positive risk association with BMI (third versus first tertile HR = 1.47
(1.01 to 2.15)) was observed. BMI was inversely associated with ER+PR+ tumors among women aged ≤49 years (per 5
kg/m
2 increase, HR = 0.79 (95%CI 0.68 to 0.91)), and positively associated with risk among women ≥65 years (HR = 1.25
(1.16 to 1.34)). Adjusting for BMI, waist and hip circumferences showed no further associations with risks of breast
cancer subtypes. Current use of HRT was significantly associated with an increased risk of receptor-negative (HRT
current use compared to HRT never use HR: 1.30 (1.05 to 1.62)) and positive tumors (HR: 1.74 (1.56 to 1.95)), although
this risk increase was weaker for ER-PR- disease (Phet = 0.035). The association of HRT was significantly stronger in the
leaner women (BMI ≤22.5 kg/m
2) than for more overweight women (BMI ≥25.9 kg/m
2) for, both, ER-PR- (HR: 1.74 (1.15
to 2.63)) and ER+PR+ (HR: 2.33 (1.84 to 2.92)) breast cancer and was not restricted to any particular HRT regime.
Conclusions: An elevated BMI may be positively associated with risk of ER-PR- tumors among postmenopausal
women who never used HRT. Furthermore, postmenopausal HRT users were at an increased risk of ER-PR- as well
as ER+PR+ tumors, especially among leaner women. For hormone-receptor positive tumors, but not for hormone-
receptor negative tumors, our study confirms an inverse association of risk with BMI among young women of
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receptor negative tumors.
Introduction
Breast cancer is a complex and heterogeneous disease with
a variety of histopathological and molecular subforms with
diverse clinical outcomes and relationships with estab-
lished risk factors [1,2]. One important subclassification of
clinical breast tumors is based on the presence or absence
of estrogen (ER) and progesterone (PR) receptors, and the
routine identification of these receptors currently guides
targeted therapies and provides important prognostic
information [3]. The expression of the hormone receptors
also broadly overlaps with more detailed molecular sub-
classifications of breast tumors as determined by microar-
ray-based gene expression profiling [4,5].
Epidemiological data indicate that associations between
excess body mass index (BMI) and the risk of breast can-
cer may differ by the ER and PR status in breast tumors
[6], and that the positive association of excess adiposity
with breast cancer risk after menopause may be driven
predominantly by the association with receptor-positive
(ER+ or ER+PR+) disease [6]. For receptor-negative breast
tumors, the association of risk with excess weight is less
well characterized, and studies have shown variable and
somewhat conflicting results [6-9]. In part, the diversity of
previous findings could be related to heterogeneity in the
association of excess weight with breast cancers diagnosed
at a predominantly premenopausal or more advanced
postmenopausal ages.
Another important factor to be accounted for when
assessing the relationships of excess adiposity with post-
menopausal breast cancer risk is use of hormone replace-
ment therapy (HRT). Various studies have shown
interactions of BMI with postmenopausal HRT use as
risk factors for breast cancer [6,10-14]. However these
interactions have not been described for hormone recep-
tor-defined breast cancer subtypes.
The present analysis extends on a previous report
(2004) from the European Prospective Investigation into
Cancer and Nutrition (EPIC) in which the relationships
of anthropometry with risk of total breast cancer were
investigated [14]. Using more recent follow-up data from
EPIC, which now includes a total of 7,174 incident cases
of breast cancer with information on ER status and 5,906
with additional PR status, we examined the relationships
of anthropometric indices of adiposity (BMI, waist and
hip circumferences) with risks of breast cancer subtypes
defined by hormone receptor status, across five-year age
bands spanning from premenopausal into postmenopau-
sal years, and accounting for past or current use of
menopausal HRT.
Materials and methods
EPIC is a multi-center prospective cohort study designed
to investigate the relationships between diet, nutrition
and metabolic factors and cancer, consisting of about
370,000 women and 150,000 men aged mostly between
25 and 70 years [15,16]. All participants were enrolled
between the years 1992 and 2000 from 23 regional and
national research centers located in 10 western European
countries: Denmark, France, Germany, Greece, Italy, The
Netherlands, Norway, Spain, and the United Kingdom.
Extensive details about the standardized procedures for
recruitment, measuring baseline anthropometry (height,
weight, waist and hip circumferences), questionnaires on
current habitual diet, reproductive and menstrual history,
exogenous hormone use (oral contraceptive (OC) and
HRT use), medical history, lifetime smoking and alcohol
consumption history, occupation, level of education and
physical activity and biological sample collection at study
centers are given elsewhere [15,16]. All subjects gave writ-
ten informed consent to use their questionnaire data and
the Internal Review Boards (IRB) of International Agency
for Research on Cancer (IARC) and all EPIC recruitment
centers approved the analyses based on EPIC participants.
Study participants
Of the 367,903 female participants in EPIC, women were a
priori excluded if they had a history of cancer prior to
recruitment (n = 19,853) or were missing a diagnosis or
censoring date (n = 2,892), thus leaving 345,158 partici-
pants. Three EPIC study centers did not provide any infor-
mation on breast tumor receptor status and, therefore,
were also systematically excluded from this analysis (n =
26,091). Women were further excluded if they were miss-
ing questionnaire data (n = 526) or data on height and
weight (n = 3,865). This left a total cohort of 314,676
women from 10 countries for our present analysis.
Classification of body measurements and baseline
variables
The details of standardized procedures for measuring
anthropometry and baseline variables at study centers
have previously been reported [17]. Height, waist and hip
circumferences were measured to the nearest centimeter
a n dw e i g h tt ot h en e a r e s tk i l o g r a m .M o s ts u b j e c t sh a d
their height, weight, hip and waist circumferences mea-
sured in light clothing and without shoes. Waist circum-
ference was measured by either the narrowest torso
c i r c u m f e r e n c eo rm i d w a yb e t w e e nt h el o w e rr i b sa n dt h e
iliac crest. The hip circumference was measured from
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index (BMI) was constructed by dividing weight by
height in meters squared (kg/m
2). In Norway, Umea and
a large proportion of the EPIC cohort in France (69%)
subjects’ height and weight were measured and self-
reported by the cohort participants themselves, following
detailed instructions [16,17]. Waist and hip circumfer-
ences measurements were not collected from these cen-
ters. In Oxford, subjects also self-reported their height,
weight, and waist and hip circumferences; however, a
subset of these participants were also measured by study
researchers in order to calibrate self-reported measure-
ments of the Oxford cohort [18].
Women were considered postmenopausal at recruit-
ment if they had had no menstrual cycles in the last 12
months, were older than 55 years (if the menstrual cycle
history was missing), or had a bilateral oophorectomy.
Women who reported having had a hysterectomy but still
had either one or both ovaries intact had their menopausal
status classified using their reported menstrual history, age
and exogenous hormone use. Women were classified with
a peri/-or of unknown menopausal status if they had
experienced one to nine menstrual cycles in the last 12
months, were aged 46 to 55 years if menstrual cycle his-
tory was missing, or were taking HRT at the time of
recruitment. Women were deemed premenopausal if they
had had ≥10 menstrual cycles in the last 12 months or
were younger than 46 years if the menstrual cycle history
was missing. Women who were < 46 years of age, still had
one or both ovaries and were still menstruating were con-
sidered as premenopausal if they indicated exogenous
hormone use.
Information on postmenopausal hormone use was
derived from country-specific baseline questionnaires cov-
ering ever and current use of HRT, brand name used at
recruitment and age at start and duration of use [19]. Of
the women who reported HRT ever or current use at
baseline, subgroups of different HRT regimes were created
(current estrogen only or current estrogen plus progestin
users (estrogen with sequential or continuous daily use of
progestin)). Duration of HRT use and time since last use
(created by combining information of duration of past use
and age at starting HRT) was restricted to information
collected at baseline recruitment.
Perspective ascertainment of breast cancer cases and the
coding of receptor status
In all countries (except for France, Germany and Greece)
incident breast cancer cases were identified using record
linkage with cancer and pathology registries. In France,
Germany, and Greece, cancer occurrence was prospec-
tively ascertained through linkage with health insurance
records and regular direct contacts with participants and
their next of kin, and all reported breast cancer cases
were then systematically verified against clinical and
pathological records. Cancer incidence data were classi-
fied according to the International Classification of Dis-
eases, 10
th Revision (ICD-10). Information on tumor
receptor status, as well as the available laboratory meth-
ods and quantification descriptions used to determine
receptor status was collected by 20 centers. To standar-
dize the quantification of receptor status received from
the EPIC centers, the following criteria for a positive
receptor status were used; ≥10% cells stained, any ‘plus-
system’ description, ≥20 fmol/mg, an Allred score of ≥3,
an IRS ≥2, or an H-score ≥10 [20-24].
Vital status was collected from regional or national
mortality registries. The last updates of endpoint data for
cancer incidence and vital status were between 2005 and
2010, depending on the center. Women were considered
at risk from the time of recruitment until breast cancer
diagnosis or censoring (age at death, loss to follow-up,
end of follow-up, or diagnosis of other cancer cases).
T h r e eE P I Cs u b j e c t sh a dt h es a m ed a t eo fr e c r u i t m e n t
and date of exit and were excluded because they did not
contribute to the underlying time at risk variable. An
additional three subjects with a breast cancer diagnosis
were excluded because it was unclear whether their diag-
nosis was a primary incidence case, thus a total of 9,530
breast cancer cases were included for this analysis. A
total of 7,174 breast cancer cases had information on ER
status (5,764 ER-positive, 1,410 ER-negative); of which,
5,906 had further information on PR status (3,586 ER+PR
+, 1,086 ER+PR-, 213 ER-PR+, 1,021 ER-PR-).
Statistical analysis
Correlations between indices of adiposity were assessed
using Pearson’s partial correlation adjusted for study cen-
ter and age at recruitment. Associations between BMI,
waist and hip circumferences and the risk of breast can-
cer subtype were evaluated using Cox proportional
hazards models to estimate hazard ratios (HR) and 95%
confidence intervals (CI), with total breast cancer cases
and breast cancer subtype outcomes defined as either
jointly classified ER+PR+, ER+PR-, ER-PR+, ER-PR- or
missing receptor status, ER-positive, ER-negative or miss-
ing receptor status, or, PR-positive, PR-negative or miss-
ing receptor status. All multivariable analyses were
stratified by age in one-year categories and by study cen-
ter, to prevent violations of the proportional-hazards
assumption.
To analyze associations of BMI, waist and hip circumfer-
ences with risks of breast cancer subtypes in all women,
age bands were created by counting person years within
each age limit, with left and/or right side censoring age
limits defined as ‘less than or equal to 49 years’, ‘between
50 and 54 years’, ‘between 55 and 59 years’, ‘between 60
and 64 years’ and ‘65 years and older’. Incidence rates of
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and observed numbers of incident cases within age bands.
Anthropometric measures were examined across the age
bands on a continuous scale.
BMI has been observed to interact with postmenopausal
HRT use [11,14,25], and to eliminate any possible interac-
tion effects, the association of BMI, waist and hip circum-
ferences were analyzed within the group of HRT never
users only. Differences in recording baseline HRT use
across the EPIC centers caused difficulties in establishing
the reliability of baseline HRT use for younger women
(less than 55 years at recruitment) who were still pre- or
perimenopausal. Therefore, we restricted the analyses by
age bands for baseline never users of HRT to women aged
55 years and over. Furthermore, possible interactions
between HRT use (never, past and current) and BMI were
assessed with respect to risks of the breast cancer subtypes
among postmenopausal women only.
In postmenopausal women, BMI tertiles were created
using cut-points based on the overall cohort distribution
of body measurements (BMI tertile 1: ≤22.5 kg/m
2;B M I
t e r t i l e2 :2 2 . 6t o2 5 . 8k g / m
2;B M It e r t i l e3 :≥25.9 kg/m
2).
Combined risk categories of BMI (tertiles) and HRT use
were constructed using never users with a BMI in the
lowest tertile as the reference category. Statistical interac-
tion between categories of HRT use (never versus current
use) and the integer score of BMI tertiles (1,2,3) entered
as an ordered, quantitative variable was assessed by
including an interaction term and the log likelihood ratio
test.
A multivariable model stratified by center and age at
recruitment with further adjustments for age at menarche
(less than 11 years, 11 to 14 years and greater than 14
years, missing), age at first child birth (less than 20 years,
20 to 30 years, greater than 30 years, missing), parity (nul-
liparous, one full-term birth, two full-term births or three
or more full-term births, missing), history of breastfeeding
(ever versus never, missing), use of oral contraceptives
(OC) (ever versus never, missing), smoking status (current,
former, never, missing), alcohol consumption (nonconsu-
mers (< 1.5 g/day), 1.5 g to 10 g/day (as the reference cate-
gory), 10 to 20 g/day, 20 to 30 g/day and greater than
30 g/day, missing), physical activity (Cambridge Index:
active, moderately active, moderately inactive and inactive,
missing [26]), education level (none, primary school, tech-
nical/professional school, secondary school, university
degree or equivalent, missing), HRT use (ever versus
never, missing) and age at menopause in postmenopausal
women only was assessed. Both the reduced model strati-
fied by age and center and the multivariable model are
presented; however, as the risk estimates were very similar
only the reduced model results are discussed. In addition,
adjustments for BMI (as a continuous variable) were used
to examine whether measures of body distribution (waist
circumference, hip circumference) were associated with
breast cancer risk independently of general excess weight.
Differences between BMI, waist and hip circumfer-
ences and risk of breast cancer subtypes were analyzed
using the data augmentation method as described by
Lunn and McNeil, using a log likelihood ratio test to
compare the model with and without interaction terms
between the anthropometric variable and breast cancer
subtype [27]. Women who developed the competing
breast cancer subtype or were missing receptor status
were also censored at the time of occurrence [27].
A sensitivity analysis that excluded all uncalibrated self-
reported anthropometric measurements to assess the
effect of including self-reported indices of BMI, waist and
hip circumferences into the models found no difference
between how measurements of anthropometry were
obtained (data not shown) so, therefore, all self-reported
anthropometric measurements were retained in the mod-
els. All tests of significance were two-sided and all analyses
were completed using SAS version 9.2; SAS Institute,
Cary, NC.
Results
A total cohort of 314,760 women was followed for a sum
of 3,399,178 person years. Of these, 144,223 (45.8%) were
postmenopausal at the time of recruitment, of which
93.6% had a natural menopause. Baseline characteristics of
all women and postmenopausal women within this cohort
are presented in Table 1. The median age at recruitment
from the EPIC centers was 50.9 years for all women, 58.1
for women who were postmenopausal, 42.6 for women
who were premenopausal and 50.1 for women whose
menopausal status was either perimenopausal or undeter-
mined at baseline. Of the postmenopausal women who
provided information on HRT use, 42,719 (29.6%) were
current users at recruitment, 18,278 (12.7%) were past
users and 78,919 (54.7%) were never users. Postmenopau-
sal women of higher degrees of BMI were more likely to
be never users of HRT and had a shorter duration of past
HRT use (Additional file 1 Table S1).
For the great majority of postmenopausal women who
reported HRT current use and had information of HRT
regimen (n = 35,856 (76.0%)), combinations of estrogen
plus progestin were used, while almost one out of four
HRT users (24.0%) used formulae based on estrogens
alone. Almost half of all breast cancer cases (46.2%) were
d i a g n o s e da tt h ea g eo f6 0y e a r so ro l d e r .T h em e d i a n
time until diagnosis was 6.1 years for all incident cases,
6.3 years for ER-PR- tumors, 6.8 years for ER+PR+
tumors, and 5.0 years for tumors with unknown ER or
PR receptor status. Incident cases with ER-PR- breast
tumors were rather evenly distributed across the age
bands, whereas the majority of cases with ER+PR+ breast
tumors were diagnosed after the age of 55 (Table 2).
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age bands showed that ER-PR- breast cancer rates were
stable across all age bands above age 50 (for ≤49 years:
16.9, 50 to 54 years: 34.6, 55 to 59 years: 36.9, 60 to 64
years: 38.4, ≥65 years: 29.1 per 100,000 person years),
whereas ER+PR+ disease, rates increased steadily with
increasing age albeit at a slower rate after 50 years (for
≤49 years: 44.5, 50 to 54 years: 111.2, 55 to 59 years:
125.4, 60 to 64 years: 142.6, ≥65 years: 127.9 per 100,000
person years). [28]
Across the age bands, Cox regression models showed
no distinct association for BMI with risk of ER-PR- breast
cancer (Figure 1 and Table 3). It was only among women
older than 65 years that the relative risk for ER-PR-
tumors (per five-unit increase in BMI HR = 0.95 (95%CI:
0.79 to 1.13)) was statistically different from ER+PR+
tumors (per five-unit increase in BMI HR = 1.25 (95%CI:
1.16 to 1.34); P < 0.001; Phet = 0.004). For ER+PR+
tumors, the negative risk association for BMI among
women aged less than 49 years (per five-unit increase in
BMI HR = 0.79 (95%CI: 0.68 to 0.91); P = 0.002) progres-
sively turned into a significant positive risk association
among women aged 65 years and older.
Restricting the analysis to women who never used
HRT, a five-unit increase in BMI showed a weak ten-
dency towards a risk of ER-PR- disease; although this
trend was not statistically significant across any age band.
There was an indication of heterogeneity between the
risks estimates of ER-PR- (per five-unit increase in BMI
HR = 1.06 (0.85 to 1.32)) and ER+PR+ tumors (per five-
unit increase in BMI HR = 1.34 (1.22 to 1.47)) among the
HRT never users older than 65 years (Phet = 0.05). Similar
patterns of association were observed for BMI with risk
of ER-negative versus ER-positive breast cancer subtypes,
ignoring PR status (Additional file 2, Figure S1), and as
well as PR-negative versus PR-positive breast cancer sub-
types, ignoring ER status (Additional file 3, Figure S2).
Increased waist or hip circumferences showed relative
risk patterns across the age bands that were very similar
to those for BMI, for both ER+PR+ and ER-PR- breast
cancer subtypes, among all women as well as among cur-
rent and past users of HRT (Additional files 4 and 5,
Figures S3 and S4). After adjustment for BMI, however,
neither waist nor hip circumferences showed any rela-
tionship with risks of either breast cancer subtype (data
not shown). Pearson’s correlations showed that increases
in BMI were highly correlated with increases in both
waist and hip circumferences (Pearson’s correlations
coefficient r = 0.83 and 0.85 respectively), therefore this
could account for the lack of associations observed of
waist and hip circumferences after adjustment for BMI.
With regard to postmenopausal HRT use, Cox regres-
sion models showed that in comparison to HRT never
users, postmenopausal women who were current HRT
users at baseline had significantly increased risks of both
ER-PR- breast cancer (HR = 1.30 (95%CI: 1.05 to 1.62);
Pvalue = 0.02) and ER+PR+ breast cancer (HR = 1.74 (95%
CI: 1.56 to 1.95); Pvalue < 0.001), although the relative risk
was significantly weaker for ER-PR- than for ER+PR+
tumors (Phet = 0.035).
For combined risk categories determined by the joint
classification of HRT use (never, past, current) and BMI
Table 1 EPIC cohort characteristics for all women and postmenopausal women at baseline recruitment, 2010.
All women Postmenopausal women BMI tertiles
6
12 3
(n = 314760) (n = 144223) (n = 36792) (n = 48846) (n = 58585)
Person years 3399178 1542924 391812 525727 625386
Age at recruitment
1 50.9(19.9-98.5) 58.1(27.8-98.5) 56.8(32.4-98.5) 57.8(32.3-94.9) 59.1(27.8-88.6)
Age at exit
1 61.9(21.1-102.4) 68.9(40.4-102.4) 67.7(40.4-102.4) 68.7(40.8-101.3) 69.8(40.5-98.3)
Years of follow-up
2 11.4(0.01-16.8) 11.5(0.01-16.7) 11.6(0.01-16.7) 11.6(0.02-16.6) 11.5(0.01-16.6)
Years until diagnosis
3 6.1(0.01-15.6) 6.0(0.01-15.3) 5.8(0.01-14.4) 6.0(0.02-14.7) 6.0(0.01-15.3)
BMI (kg/m
2)
1 24.02(10.2-77.9) 24.8(12.9-77.9) 21.1(12.9-22.5) 24.1(22.6-25-8) 28.8(25.9-77.9)
Hip circumference (cm) 100.0(50.0-179.0) 81.0(51.0-179.0) 71.0(52.0-117.0) 78.0(51.0-171.0) 90.0(52.0-179.0)
Waist circumference (cm) 78.0(50.0-179.0) 101.0(53.0-171.0) 93.0(57.0-115.0) 99.0(55.0-158.0) 107.5(53.0-171.0)
Premenopausal
4 35.5%(111560) - - - -
Peri/or of unknown menopausal status
4 18.7%(58887) - - - -
Postmenopausal
4 45.8%(144223) - - - -
Never HRT user
5 38.4%(120992) 54.7%(78,919) 45.0%(16569) 51.4%(25108) 63.6%(37242)
Past HRT user
5 7.0%(21980) 12.7%(18,278) 12.6%(4640) 13.1%(6401) 12.4%(7237)
Current HRT user
5 16.5%(51975) 29.6%(42,719) 39.8%(1462) 32.4%(15826) 20.9%(12266)
Missing HRT use
5 38.0%(119723) 3%(4,307) 2.6%(956) 3.1%(1511) 3.1%(1840)
1Median (range);
2reverse Kaplan Meier median (range);
3in primary incident cases only;
4percentage (number);
5excluding premenopausal women at baseline
recruitment;
6in postmenopausal women at baseline recruitment only. BMI, body mass index; HRT, hormone replacement therapy.
Ritte et al. Breast Cancer Research 2012, 14:R76
http://breast-cancer-research.com/content/14/3/R76
Page 5 of 14tertiles, for ER-PR- breast cancer, using never users of
HRT in the lowest BMI tertile as a reference category,
the highest relative risk for current HRT use was seen
for women in the first BMI tertile, while relative risks
were somewhat weaker for women in the middle and
upper tertiles of BMI (Figure 2). Within separate cate-
gories of HRT use, we observed a positive risk associa-
tion within the third tertile of BMI with ER-PR- breast
cancer among never users of HRT (third versus first ter-
tile HR = 1.47 (95%CI: 1.01 to 2.15); Ptrend =0 . 0 6 )
(Table 4) contrasted by an indication of a negative risk
association among current and no association with past
users of HRT. Switching perspective and stratifying the
analysis by separate strata of BMI, the relative risk for
current HRT use was strongest for women within the
first BMI tertile and absent for women in the higher ter-
tiles. This interaction of the effects of HRT use (current
versus never users) across BMI tertile scores was statisti-
cally significant (Pinteraction =0 . 0 3 7 )( T a b l e5 )a n dw a s
not restricted to HRT type (Additional files 6, 7, 8, 9, 10
and 11, Tables S2 to S5 and Figures S5 and S6).
For ER+PR+ breast cancer, compared to never users of
HRT in the lowest BMI tertile as a reference category, we
observed an approximate 2.5-fold increase in risk for ER
+PR+ breast cancer for baseline HRT users in each of the
three BMI tertiles when we used never users in the low-
est BMI tertile as the reference category (Figure 2). How-
ever, performing analyses within independent strata for
baseline HRT use (never, past, current), our data showed
more than a 1.8-fold increase in risk for the highest BMI
tertile compared to the lowest tertile in the strata of
never and past users of HRT, but no such association at
all among current HRT users (Table 4). Alternatively,
examining relative risks for HRT use within strata of
Table 2 Cohort size, person years and incident cases of breast cancer subtypes across five-year age bands.
Age bands
≤ 49 years 50-54 years 55-59 years 60-64 years ≥ 65 years All women
Subjects at risk 141513 175268 185404 161850 113810 314670
Person years 870491 627875 661652 565289 673872 3399178
Total cases
1 1205 (12.6%) 1770 (18.6%) 2151 (22.6%) 2065 (21.7%) 2339 (24.5%) 9530
ER-positive 507 (8.8%) 1031 (17.9%) 1402 (24.3%) 1345 (23.3%) 1479 (25.7%) 5764
ER-negative 235 (16.7%) 306 (21.7%) 320 (22.7%) 294 (20.9%) 255 (18.1%) 1410
ER-missing 463 (19.7%) 433 (18.4%) 429 (18.2%) 426 (18.1%) 605 (25.7%) 2356
PR-positive 462 (12.1%) 755 (19.8%) 872 (22.9%) 839 (22.0%) 880 (23.1%) 3808
PR-negative 212 (10.0%) 397 (18.8%) 553 (26.2%) 499 (23.6%) 453 (21.4%) 2114
PR-missing 531 (14.7%) 618 (17.1%) 726 (20.1%) 727 (20.1%) 1,006 (27.9%) 3608
ER+PR+ 390 (10.9%) 698 (19.5%) 830 (23.1%) 806 (22.5%) 862 (24.0%) 3586
ER+PR- 64 (5.9%) 180 (16.6%) 306 (28.2%) 280 (25.8%) 256 (23.6%) 1086
ER-PR+ 71 (33.3%) 57 (26.8%) 37 (17.4%) 31 (14.6%) 17 (8.0%) 213
ER-PR- 147 (14.4%) 217 (21.3%) 244 (23.9%) 217 (21.3%) 196 (19.2%) 1021
ER or PR missing 533 (14.7%) 618 (17.1%) 734 20.3% 731 (20.2%) 1008 (27.8%) 3624
1Including women of unknown receptor status. ER, estrogen receptor; PR, progesterone receptor.
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Figure 1 Hazard ratios of ER+PR+ and ER-PR- tumors for increases in BMI across age bands. All models are for a 5 kg/m
2 increase in BMI
and were stratified by age at recruitment and study center. Hazard ratio estimates are shown for all women and HRT never users. BMI, body
mass index; ER, estrogen receptor; HRT, hormone replacement therapy; PR, progesterone receptor.
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Page 6 of 14each of the BMI tertiles separately, the relative risk for ER
+PR+ breast cancer associated with current use of HRT
was strongest for women within the lowest BMI tertile,
and progressively weakened across BMI tertiles 2 and 3,
respectively (Pinteraction < 0.001)(Table 5).
Discussion
Overall, for ER-PR- tumors, our study showed no distinct
associations with BMI in any of the five-year age bands.
However, among postmenopausal women who never used
HRT, our data showed a significant BMI-related increase
in risk of receptor-negative breast cancers. As expected,
the inverse relationship of excess body weight with risk of
ER+PR+ breast cancer among women younger than 49
years progressively turned into a direct relationship among
women of more advanced age. Furthermore, we observed
increases in the risks of both hormone receptor-negative
and -positive tumors among women who used HRT at
baseline, although the increase in risk was weaker for ER-
PR- than for ER+PR+ tumors. The HRT-related increases
in risks of both ER-PR- and ER+PR+ breast cancer were
stronger among the leaner women, and this increase was
independent of HRT type. Finally, with respect to measures
of body fat distribution (waist and hip circumferences) no
relationships with either receptor-negative or -positive
breast cancer were observed after adjustment for BMI.
Table 3 Hazard ratios of joint ER and PR tumors per 5 cm increase in BMI across each age band among all women and
never users of HRT.
≤49
years
Between
50 and 54 years
Between
55 and 59 years
Between
60 and 64 years
≥65
years
Cases HR 95%CI Cases HR 95%CI Cases HR 95%CI Cases HR 95%CI Cases HR 95%CI
All women
Age and center stratified
ER+PR+ 390 0.79 (0.68-0.91) 698 0.88 (0.79-0.97) 830 1.08 (0.69-1.06) 806 1.05 (0.96-1.14) 862 1.25 (1.16-1.34)
ER+PR- 64 1.10 (0.81-1.50) 180 0.86 (0.69-1.06) 306 0.86 (0.68-1.38) 280 0.86 (0.74-1.01) 256 0.92 (0.78-1.08)
ER-PR+ 71 0.68 (0.47-0.99) 57 0.97 (0.68-1.38) 37 0.55 (0.91-1.27) 31 0.83 (0.50-1.37) 17 0.70 (0.35-1.42)
ER-PR- 147 0.89 (0.72-1.12) 217 1.08 (0.91-1.27) 244 0.98 (0.93-1.13) 217 0.95 (0.80-1.12) 196 0.95 (0.79-1.13)
ER or PR missing 533 0.92 (0.82-1.03) 618 1.03 (0.93-1.13) 734 1.03 (1.00-1.18) 731 1.02 (0.94-1.11) 1008 1.09 (1.01-1.17)
Pheterogeneity
2 0.36 0.05 0.26 0.28 0.004
Multivariable model
4
ER+PR+ 390 0.80 (0.69-0.93) 698 0.90 (0.81-1.01) 830 1.11 (1.01-1.21) 806 1.10 (1.01-1.20) 862 1.32 (1.22-1.43)
ER+PR- 64 1.14 (0.83-1.55) 180 0.90 (0.72-1.12) 306 0.90 (0.76-1.05) 280 0.88 (0.75-1.03) 256 0.97 (0.82-1.14)
ER-PR+ 71 0.67 (0.46-0.99) 57 0.98 (0.68-1.40) 37 0.57 (0.32-1.01) 31 0.84 (0.50-1.43) 17 0.79 (0.37-1.68)
ER-PR- 147 0.90 (0.71-1.13) 217 1.09 (0.92-1.29) 244 1.00 (0.84-1.18) 217 0.97 (0.81-1.16) 196 0.97 (0.81-1.17)
ER or PR missing 533 0.93 (0.83-1.05) 618 1.08 (0.98-1.19) 734 1.08 (0.99-1.18) 731 1.06 (0.97-1.16) 1008 1.13 (1.05-1.22)
Pheterogeneity
2 0.44 0.08 0.29 0.20 0.002
HRT never users
Age and center stratified
ER+PR+ 350 1.10 (0.97-1.25) 348 1.08 (0.96-1.22) 441 1.34 (1.22-1.47)
ER+PR- 135 0.87 (0.69-1.10) 118 0.95 (0.76-1.19) 138 0.96 (0.78-1.18)
ER-PR+ 16 0.63 (0.28-1.40) 10 0.74 (0.30-1.79) 8 0.98 (0.42-2.29)
ER-PR- 95 1.12 (0.88-1.42) 90 1.05 (0.83-1.33) 105 1.06 (0.85-1.32)
ER or PR missing 304 1.06 (0.94-1.21) 325 1.08 (0.96-1.22) 566 1.13 (1.03-1.24)
Pheterogeneity
2 0.94 0.83 0.05
Multivariable model
5
ER+PR+ 350 1.11 (0.97-1.27) 348 1.13 (1.00-1.28) 441 1.38 (1.25-1.52)
ER+PR- 135 0.91 (0.72-1.15) 118 0.96 (0.76-1.21) 138 1.02 (0.83-1.25)
ER-PR+ 16 0.62 (0.26-1.49) 10 0.63 (0.24-1.67) 8 1.06 (0.37-3.03)
ER-PR- 95 1.19 (0.93-1.54) 90 1.09 (0.85-1.40) 105 1.11 (0.88-1.39)
ER or PR missing 304 1.09 (0.96-1.24) 325 1.11 (0.98-1.25) 566 1.17 (1.06-1.28)
Pheterogeneity
2 0.62 0.83 0.08
1Per 5 kg/m
2 increase;
2heterogeneity between ER+PR+ versus ER-PR- tumors using data augmentation method as described by Lunn and McNeil;
3multivariable
hazard ratios were stratified for study center, age, and adjusted for height (cm), educational attainment, smoking status, alcohol consumption, parity, age at first
pregnancy, age at menarche, menopausal status, age at menopause (in postmenopausal women), ever OC use and current HRT use;
4multivariable hazard ratios
were stratified for study center, age, and adjusted for height (cm), educational attainment, smoking status, alcohol consumption, parity, age at first pregnancy,
age at menarche, ever OC use, menopausal status, age at menopause (in postmenopausal women). BMI, body mass index; CI, confidence interval; ER, estrogen
receptor; HR, hazard ratio; HRT, hormone replacement therapy; PR, progesterone receptor.
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Page 7 of 14Cancer registry data show that overall breast cancer
incidence increases with age. However, after the age of
50, rates of hormone receptor-negative disease no longer
increase with advancing age, whereas the incidence rates
of ER-positive tumors continue, albeit at a reduced pace
compared to earlier ages [29-33]. This age-related pat-
tern of incidence rates of ER-PR- and ER+PR+ tumors
was also apparent in our data. The change in the age-
related rise in incidence rates after age 50 suggests a
possible relationship of both receptor-negative and
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Figure 2 Hazard ratios of ER+PR+ and ER-PR- tumors for increases in BMI across HRT user categories. All models were restricted to
postmenopausal women with information on baseline HRT use and stratified by age at recruitment and study center. HRT never users within
BMI tertile1 were used as the reference category. BMI tertile 1: ≤22.5 kg/m
2; BMI tertile 2: 22.6 to 25.8 kg/m
2; BMI tertile 3: ≥25.9 kg/m
2. BMI,
body mass index; ER, estrogen receptor; HRT, hormone replacement therapy; PR, progesterone receptor.
Table 4 Hazard ratios of ER+PR+ and ER-PR- tumors across levels of BMI within categories of postmenopausal HRT
users.
HRT use BMI tertile
1
12 3 Per 5 kg/m
2 increase
Cases Reference Cases HR 95% CI Cases HR 95% CI Cases
ER+PR+
Age and center stratified
Never user 125 1.00 248 1.44 (1.15-1.78) 392 1.80 (1.46-2.23) 765 1.24 (1.15-1.34)
Past user 49 1.00 81 1.45 (1.01-2.09) 95 1.85 (1.27-2.69) 225 1.45 (1.25-1.68)
Current user 296 1.00 312 1.03 (0.87-1.21) 200 0.74 (0.50-1.09) 808 0.99 (0.89-1.09)
ER+PR+
Multivariable model
2
Never user 125 1.00 248 1.47 (1.18-1.82) 392 1.90 (1.53-2.35) 765 1.28 (1.18-1.38)
Past user 49 1.00 81 1.43 (0.99-2.07) 95 1.89 (1.29-2.77) 225 1.47 (1.26-1.72)
Current user 296 1.00 312 1.04 (0.88-1.23) 200 0.95 (0.78-1.15) 808 1.01 (0.91-1.12)
ER-PR-
Age and center stratified
Never user 41 1.00 80 1.40 (0.96-2.06) 103 1.47 (1.01-2.15) 224 1.07 (0.93-1.25)
Past user 19 1.00 29 1.20 (0.66-2.20) 69 0.80 (0.40-1.60) 117 0.86 (0.62-1.19)
Current user 79 1.00 69 0.82 (0.59-1.15) 45 0.74 (0.50-1.09) 193 0.79 (0.63-0.98)
ER-PR-
Multivariable model
Never user 41 1.00 80 1.44 (0.98-2.11) 103 1.59 (1.08-2.34) 224 1.12 (0.96-1.31)
Past user 19 1.00 29 1.18 (0.64-2.18) 69 0.76 (0.37-1.56) 117 0.82 (0.58-1.16)
Current user 79 1.00 69 0.82 (0.59-1.15) 45 0.77 (0.52-1.14) 193 0.80 (0.64-1.01)
1BMI tertile 1: ≤22.5 kg/m
2; BMI tertile 2: 22.6 to 25.8 kg/m
2; BMI tertile 3: ≥25.9 kg/m
2;
2 multivariable hazard ratios were stratified for study center, age, and
adjusted for height (cm), educational attainment, smoking status, alcohol consumption, parity, age at first pregnancy, age at menarche, ever OC use, menopausal
status, age at menopause. BMI, body mass index; CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; HRT, hormone replacement therapy; PR,
progesterone receptor.
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Page 8 of 14-positive breast cancer with the menopause-related ces-
sation of ovarian estrogen and/or progesterone synthesis
[29]. While a wide array of epidemiologic, clinical and
experimental evidence has clearly established a late-
stage growth-promoting effect of estrogens, especially
on estrogen-sensitive tumors [34], there is substantial
evidence that estrogens may also play an important role
in earlier evolutionary stages of the development of both
ER-negative and -positive tumor types [29,35,36].
Indeed, evidence suggests that a large proportion of ER-
negative tumors may arise from estrogen-responsive
precursor tumors or cells and that estrogen sensitivity
may be lost at later stages of tumor development [35].
In addition, mammary stem cells have been shown to be
responsive to sex steroid hormones despite not having a
clear expression of an ER or PR [37].
For ER-PR- tumors, our findings across the age-bands
are consistent with those from the meta-analysis by
Suzuki et al. (2009) [6] of nine cohort and twenty-two
case control studies, which also showed no association
of BMI with risk of ER-PR- tumors in either premeno-
pausal (1481 cases) or postmenopausal women (1522
cases). However, when our analysis was restricted to
postmenopausal women who never used HRT, BMI was
associated with ER-PR- tumors. A recent analysis of the
Nurses’ Health Study II cohort showed a more than
two-fold increase in risk of ER-negative premenopausal
breast cancer (n = 131) for women in higher categories
of BMI, waist and hip circumferences [38]. In addition,
an analysis within the Women’s Health Initiative cohort
[ 3 9 ]s h o w e dam o d e r a t ei n c r e a s ei nr i s ko ft r i p l e - n e g a -
tive (ER-/PR-/HER2-) breast tumors among postmeno-
pausal women who had more elevated BMI (HR = 1.35
(95%CI = 0.92 to 1.99) for the top versus bottom quar-
tiles of BMI).
For receptor-positive tumors, our findings on the rela-
tionships of risk with BMI are well in line with those
from previous epidemiologic studies. The meta-analysis
by Suzuki et al. showed a 33% increase in risk of ER+PR+
tumors per five-unit increase in BMI among postmeno-
pausal women (5,469 cases; risk estimate (RE) = 1.33
(95%CI = 1.20 to 1.48)), and a 10% reduction in risk of
ER+PR+ disease among premenopausal women (2,643
cases; RE = 0.90 (95%CI = 0.82 to 0.99)) [6]. Furthermore,
similar to our observations, this meta-analysis showed a
somewhat stronger association of BMI with risk of hor-
mone ER+PR+ tumors for women who did not use HRT
[6]. Finally, still in line with our findings, one recent
Table 5 Hazard ratios of ER+PR+ and ER-PR- tumors for categories of postmenopausal HRT use within tertiles of BMI.
BMI tertile
3 HRT use
Never user Past user Current user
Cases Reference Cases HR 95% CI Cases HR 95% CI Pinteraction
2
ER+PR+
Age and center stratified
BMI tertile 1 125 1.00 49 1.18 (0.84-1.65) 296 2.33 (1.84-2.92) < 0.001
BMI tertile 2 248 1.00 81 1.10 (0.85-1.42) 312 1.75 (1.45-2.12)
BMI tertile 3 392 1.00 95 1.11 (0.88-1.39) 200 1.45 (1.19-1.77)
ER+PR+
Multivariable model
3
BMI tertile 1 125 1.00 49 1.17 (0.83-1.64) 296 2.32 (1.84-2.92) < 0.001
BMI tertile 2 248 1.00 81 1.10 (0.85-1.42) 312 1.75 (1.45-2.11)
BMI tertile 3 392 1.00 95 1.11 (0.88-1.39) 200 1.45 (1.19-1.76)
ER-PR-
Age and center stratified
BMI tertile 1 41 1.00 19 1.38 (0.79-2.43) 79 1.74 (1.15-2.63) 0.037
BMI tertile 2 80 1.00 29 1.20 (0.78-1.86) 69 1.07 (0.75-1.54)
BMI tertile 3 103 1.00 20 0.92 (0.57-1.51) 45 1.21 (0.81-1.81)
ER-PR-
Multivariable model
BMI tertile 1 41 1.00 19 1.38 (0.79-2.43) 79 1.74 (1.15-2.63) 0.037
BMI tertile 2 80 1.00 29 1.18 (0.77-1.83) 69 1.08 (0.75-1.55)
BMI tertile 3 103 1.00 20 0.92 (0.57-1.51) 45 1.21 (0.81-1.81)
1BMI tertile 1: ≤22.5 kg/m
2; BMI tertile 2: 22.6 to 25.8 kg/m
2; BMI tertile 3: ≥25.9 kg/m
2;
2P for interaction was calculated using the log likelihood ratio test for
models with and without the interaction term for HRT never and current use by BMI tertiles;
3multivariable hazard ratios were stratified for study center, age, and
adjusted for height (cm), educational attainment, smoking status, alcohol consumption, parity, age at first pregnancy, ever OC use, age at menarche, menopausal
status, age at menopause. BMI, body mass index; CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; HRT, hormone replacement therapy; PR,
progesterone receptor.
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Page 9 of 14prospective study also showed an inverse relationship of
BMI with breast cancer risk in premenopausal women
that was restricted to ER-positive tumors [40], and
another recent study showed that the direct risk associa-
tion of BMI with ER-positive cancers was stronger
among postmenopausal women who did not use HRT
[39].
The direct risk association of general obesity with
both ER-PR- and ER+PR+ breast cancer in postmeno-
pausal women not using HRT, may be explained by
adiposity-related increases in circulating estrogen levels,
due to conversion of androgens into estrogens within
adipose tissue [41]. The restriction of BMI-related risks
to HRT nonusers is plausible, because HRT use is a
dominant source of circulating estrogens and progestins
i np o s t m e n o p a u s a lw o m e n[ 4 2 ]t h a ta u g m e n t sb l o o d
concentrations to levels equaling those in premenopau-
sal women, compared to which adiposity-related effects
on endogenous synthesis are small.
The mechanisms that underlie the inverse association
of BMI with risk of ER+PR+ tumors among women of
reproductive age are still largely unclear [43]. Although
it has been speculated that obesity-related reductions in
circulating estrogen levels and/or reductions in circulat-
ing progesterone (due to chronic anovulation) could
play a role [44], epidemiological studies of breast cancer
risk in relation to premenopausal blood levels of proges-
terone and estrogens provide no direct support for this
[44,45].
An important observation in our study is that current
u s e r so fH R T ,c o m p a r e dt ow o m e nw h od i dn o tu s e
HRT, had higher relative risks of both receptor-negative
and -positive, but with a stronger increase in risk for the
ER+PR+ subtype. Some previous prospective studies
have documented similar increases in risks of both ER-
negative and -positive breast tumors [46,47], especially
among users of combined estrogen-plus-progestin regi-
mens [47-49], whereas other studies showed such
increases only for ER-positive disease [9,50].
Another significant observation in our study was that
for both breast cancer subtypes the increased risk asso-
ciation in current HRT users depended upon a women’s
BMI. For receptor-negative and -positive breast cancers,
HRT-related increases in risk were stronger among the
leaner women and was not restricted to a particular HRT
type. Switching perspectives, this statistical interaction
also manifested itself in a lack of BMI-related breast can-
cer risks for both receptor-negative and -positive tumors
among current HRT users. A previous analysis of the
EPIC data [14] and several other studies [6,10-13,50,51]
have shown an inverse association of BMI with the risk
of breast cancer overall among HRT users and, from our
present analysis, it appears that this overall inverse rela-
tionship could be attributable to a relative attenuation of
the HRT-related increase in risk in receptor-negative and
-positive tumors among more obese women. The endo-
crine or other mechanisms that may underlie this
attenuation of the HRT-related risk remains elusive.
The stronger association of HRT use in lean women in
comparison to more overweight women could be poten-
tially related to the different patterns of HRT use. As
expected, we observed, a higher proportion of current
use in lean women. Within past users of HRT, women of
a higher BMI tended to have a shorter cumulative dura-
tion of HRT use. Although data was restricted to infor-
mation collected at baseline, risk estimates in past and
current users were not affected by adjustment for dura-
tion of use (data not shown).
It is important to acknowledge the limitations of our
study. The determination of ER and PR status in breast
tumors is a standard part of breast cancer diagnosis used
to predict endocrine therapy response [3]. Nevertheless,
while a number of studies have shown that the classifica-
tion of the ER and PR in tumors is relatively robust
[52,53], the accuracy of classifying an ER- or PR-negative
tumor remains controversial [54,55]. Within the EPIC
cohort, as in most other studies, the classification of
breast cancer as receptor-positive and -negative (ER, PR
or joint ERPR) is based upon a variety of laboratory assay
types and quantification methods, reflecting pathology
practices across Europe and time. Recently, recommen-
dations were made to lower the threshold of the percen-
tage of stained cells from ≥10% to ≥1% to indicate
receptor-positive tumors [56,57], and some of our breast
cancer cases classified as ER-negative or PR-negative
might have been actually receptor-positive tumors
according to these newest criteria. A further limitation of
our study is the lack of prospective follow-up information
of both BMI and HRT use after recruitment.
Major strengths of the present study are its prospective
design and large number of incident cases with receptor
information. This large number of cases allowed in-depth
analyses of BMI-related relative risk patterns across age
bands, describing risk associations and their progressive
changes from premenopausal to late postmenopausal
age. Furthermore, the large case numbers allowed the
examination of interaction effects between excess body
weight and use of postmenopausal HRT and by HRT
type.
Conclusion
In summary, we found for receptor-negative tumors,
increased BMI among postmenopausal women was asso-
ciated with risk of receptor-negative tumors, however,
only in never users of HRT. In previous studies, excess
body weight was associated with an inverse risk only of
receptor-positive breast cancer in women aged less than
49, which progressively turned into an increased risk of
Ritte et al. Breast Cancer Research 2012, 14:R76
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Page 10 of 14receptor-positive disease as women aged. Furthermore,
women who reported current HRT use at baseline were
at an increased risk of both receptor-negative and -posi-
tive breast cancer, although this increase was stronger
for receptor-positive tumors. In both receptor-negative
and -positive breast cancers our data show a stronger
HRT-related increase in risk among leaner than among
more obese women. This latter interaction also meant
that BMI-related increases in risks of receptor-negative
and -positive breast cancers were observed among
nonusers of HRT only, whereas a possible BMI-related
relative decrease (receptor-negative disease) or no
increase in risk (receptor-positive disease) may be seen
among current users of HRT.
Additional material
Additional file 1: Proportions and patterns of postmenopausal HRT
use across BMI tertiles
1.
1BMI tertile 1: < 22.5 kg/m
2; BMI tertile 2: 22.6
to 25.8 kg/m
2; BMI tertile 3: > 25.9 kg/m
2. Duration and time since HRT
use are for past users of HRT, as reported at baseline recruitment.
Additional file 2: Hazard ratios of ER-positive and ER-negative
tumors for increased BMI across five-year age bands. All models are
for a 5 kg/m
2 increase in BMI and were stratified by age at recruitment
and study center. Hazard ratio estimates are shown for all women and
HRT never users.
Additional file 3: Hazard ratios of PR-positive and PR-negative
tumors for increased BMI across five-year age bands. All models are
for a 5 kg/m
2 increase in BMI and were stratified by age at recruitment
and study center. Hazard ratio estimates are shown for all women and
HRT never users.
Additional file 4: Hazard ratios of joint ER+PR+ and ER-PR- tumors
for increased waist circumference across five-year age bands. All
models are for a 5 kg/m
2 increase in BMI and were stratified by age at
recruitment and study center. Hazard ratio estimates are shown for all
women and HRT never users.
Additional file 5: Hazard ratios of joint ER+PR+ and ER-PR- tumors
for increased hip circumference across each age band. All models
are for a 5 kg/m
2 increase in BMI and were stratified by age at
recruitment and study center. Hazard ratio estimates are shown for all
women and HRT never users.
Additional file 6: Hazard ratios of ER+PR+ and ER-PR- tumors for
postmenopausal estrogen plus progestin HRT user categories
within tertiles of BMI
2. Hazard ratios of ER+PR+ and ER-PR- tumors for
estrogen plus progestin HRT user categories within tertiles of BMI. All
models are stratified by age at recruitment and EPIC center. BMI tertile 1:
< 22.5 kg/m
2; BMI tertile 2: 22.6 to 25.8 kg/m
2; BMI tertile 3: > 25.9 kg/
m
2. Estrogen plus progestin HRT use at baseline recruitment. Assessment
for interaction between BMI and HRT user categories was calculated
using the log likelihood ratio test for models with and without the
interaction term for HRT never and current use by BMI tertiles.
Additional file 7: Hazard ratios of ER+PR+ and ER-PR- tumors across
levels of BMI within categories of postmenopausal estrogen plus
progestin HRT users. Hazard ratios of ER+PR+ and ER-PR- tumors across
BMI tertiles and per 5 kg/m
2 in estrogen plus progestin HRT user
categories. All models are stratified by age at recruitment and EPIC
center. BMI tertile 1: < 22.5 kg/m
2; BMI tertile 2: 22.6 to 25.8 kg/m
2; BMI
tertile 3: > 25.9 kg/m
2.
Additional file 8: Hazard ratios of ER+PR+ and ER-PR- tumors for
postmenopausal estrogen only HRT user categories within tertiles
of BMI. Hazard ratios of ER+PR+ and ER-PR- tumors for estrogen-only
HRT user categories within tertiles of BMI. All models are stratified by age
at recruitment and EPIC center. BMI tertile 1: < 22.5 kg/m
2; BMI tertile 2:
22.6 to 25.8 kg/m
2; BMI tertile 3: > 25.9 kg/m
2. Estrogen-only HRT use at
baseline recruitment. Assessment for interaction between BMI and HRT
user categories was calculated using the log likelihood ratio test for
models with and without the interaction term for HRT never and current
use by BMI tertiles.
Additional file 9: Hazard ratios of ER+PR+ and ER-PR- tumors across
levels of BMI within categories of postmenopausal estrogen only
HRT users. Hazard ratios of ER+PR+ and ER-PR- tumors across levels of
BMI tertiles and per 5 kg/m
2 in estrogen-only HRT user categories. All
models are stratified by age at recruitment and EPIC center BMI tertile 1:
< 22.5 kg/m
2; BMI tertile 2: 22.6 to 25.8 kg/m
2; BMI tertile 3: > 25.9 kg/
m
2.
Additional file 10: Hazard ratios of ER+PR+ and ER-PR- tumors
across BMI tertiles within E+P
1 HRT user categories.
1Combined
estrogen and progesterone HRT. All models were restricted to
postmenopausal women with information on baseline HRT use and
stratified by age at recruitment and study center. HRT never users within
BMI tertile1 were used as the reference category. BMI tertile 1: ≤22.5 kg/
m
2; BMI tertile 2: 22.6 to 25.8 kg/m
2; BMI tertile 3: ≥25.9 kg/m
2.
Additional file 11: Hazard ratios of ER+PR+ and ER-PR- tumors
across BMI tertiles within E-only
1 HRT user categories.
1Estrogen-only
HRT. All models were restricted to postmenopausal women with
information on baseline HRT use and stratified by age at recruitment and
study center. HRT never users within BMI tertile1 were used as the
reference category. BMI tertile 1: ≤22.5 kg/m
2; BMI tertile 2: 22.6 to 25.8
kg/m
2; BMI tertile 3: ≥25.9 kg/m
2.
Abbreviations
BMI: body mass index; CI: confidence interval; EPIC: European Prospective
Investigation into Cancer and Nutrition; ER: estrogen receptor; HR: hazard
ratio; HRT: hormone replacement therapy; OC: oral contraceptives; PR:
progesterone receptor; RE: risk estimate.
Acknowledgements
We would like to thank Jutta Schmitt and Jutta Kneisel for their assistance
during the collection of hormone receptor status data, and we thank all the
EPIC cohort participants for their contributions to data collection at baseline
recruitment and during follow-up. Finally, the in-depth comments from the
two anonymous reviewers are also greatly acknowledged. This work was
(partly) supported by a grant from the German Research Foundation,
Graduiertenkolleg 793: Epidemiology of communicable and chronic
noncommunicable diseases and their interrelationships. The coordination of
EPIC is financially supported by the European Commission Directorate
General for Health and Consumer Protection (DG-SANCO) and the
International Agency for Research on Cancer. The national cohorts are
supported by the Danish Cancer Society (Denmark); Ligue contre le Cancer,
Mutuelle Générale de l’Education Nationale, and the Institut National de la
Santé et de la Recherche Médicale (France); Deutsche Krebshilfe, Deutsches
Krebsforschungszentrum and the Federal Ministry of Education and Research
(Germany); the Hellenic Health Foundation, the Stavros Niarchos Foundation
and the Hellenic Ministry of Health and Social Solidarity; the Italian
Association for Research on Cancer (AIRC) and the National Research Council
(Italy); the Dutch Ministry of Public Health, Welfare and Sport (VWS),
Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention
Funds, Dutch ZON (Zorg Onderzoek Nederland), World Cancer Research
Fund (WCRF), and Statistics Netherlands (The Netherlands); ERC-2009-AdG
232997 and Nordforsk, the Nordic Centre of Excellence programme on Food,
Nutrition and Health. (Norway); the Health Research Fund (FIS), Regional
Governments of Andalucía, Asturias, Basque Country, Murcia (number 6236)
and Navarra, and ISCIII RTICC Red Temática de Investigación Cooperativa en
Cáncer (R06/0020) (Spain); the Swedish Cancer Society, Swedish Scientific
Council and the Regional Government of Skåne and Västerbotten (Sweden);
Cancer Research UK, and the Medical Research Council, (United Kingdom).
Author details
1Division of Cancer Epidemiology, German Cancer Research Center (DKFZ),
Im Neuenheimer Feld TP4, Heidelberg, 69120, Germany.
2Department of
Ritte et al. Breast Cancer Research 2012, 14:R76
http://breast-cancer-research.com/content/14/3/R76
Page 11 of 14Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei
Tumori, Via Venezian 1, Milan, 20133, Italy.
3Institute of Cancer Epidemiology,
Danish Cancer Society, Strandboulevarden 49, Copenhagen, 2100, Denmark.
4Department of Cardiology, Aalborg Hospital, Aarhus University Hospital,
Hobrovej 18-22, Aalborg, 9100, Denmark.
5Department of Epidemiology,
School of Public Health, Aarhus University, Bartholins Allé 2, Aarhus, 8000,
Denmark.
6Centre for Research in Epidemiology and Population Health,
INSERM, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif, F-94805,
France.
7Paris South University, UMRS 1018, Villejuif, F-94805, France.
8Division of Cancer Epidemiology and Prevention, Institute of Social and
Preventive Medicine, Hirschengraben 84, Zurich, CH-8001, Switzerland.
9Department of Epidemiology, German Institute of Human Nutrition,
Potsdam-Rehbruecke, Arthur-Scheunert-Allee 114-116, Nuthetal, 14558,
Germany.
10WHO Collaborating Center for Food and Nutrition Policies,
Department of Hygiene, Epidemiology and Medical Statistics, University of
Athens Medical School, Asias Street 75 M., Goudi, Athens, GR-115 27, Greece.
11Hellenic Health Foundation, Tetrapoleos Street 10-12, Athens, GR-115 27,
Greece.
12Department of Epidemiology, Harvard School of Public Health,
Huntington Avenue 677, Boston, MA 02115, USA.
13Bureau of Epidemiologic
Research, Academy of Athens, Panepistimiou Street 28, Athens, GR-106 79,
Greece.
14Molecular and Nutritional Epidemiology Unit, Cancer Research and
Prevention Institute (ISPO), Scientific Institute of Tuscany, Via Cosimo il
Vecchio 2, Florence, 50139, Italy.
15Nutritional Epidemiology Unit, Fondazione
IRCCS Istituto Nazionale dei Tumori, Via Venezian1, Milano, 20133, Italy.
16Department of Clinical and Experimental Medicine Medical School
Federico II University Via S. Pansini 5 Naples, 80131, Italy.
17Cancer Registry
and Histopathology Unit, ‘Civile M.P. Arezzo’ Hospital ASP 7, Via Dante 109,
Ragusa, 97100, Italy.
18Centre for Environment and Health School of Public
Health, Imperial College London, South Kensington Campus, London SW7
2AZ, UK.
19Human Genetics Foundation (HuGeF), Via Nizza 52, Torino,10126,
Italy.
20Public Health and Health Planning Directorate, C/Ciriaco Miguel Virgil
9, Asturias, CP 33006, Spain.
21Unit of Nutrition, Environment and Cancer,
Cancer Epidemiology Research Programme, Catalan Institute of Oncology
(ICO-IDIBELL), Avda Gran Via 199-203, Barcelona, 08907, Spain.
22Andalusian
School of Public Health, Cuesta del Observatorio 4, Granada, E-1801, Spain.
23CIBER de Epidemiología y Salud Pública (CIBERESP), C/Melchor Fernández
Almagro 3-5, Madrid, 28029, Spain.
24Public Health Division of Gipuzkoa,
Institute BIO Donostia, Health Department, Basque Region, Avda de Navarra
4, Gipuzkoa, 20013, Spain.
25Department of Epidemiology, Murcia Regional
Health Authority, Ronda de Levante 11, Murcia, 30008, Spain.
26Navarra
Public Health Institute, Leyre 15, Pamplona, 31003, Spain.
27Department of
Surgery and Perioperative Sciences, Umeå University Hospital, Building 10:1
Umeå, SE-901 85, Sweden.
28Department of Oncology and Radiation
Sciences, Oncology, Umeå University Hospital, Building 6M, Umeå, SE-901 87,
Sweden.
29National Institute for Public Health and the Environment, Antonie
van Leeuwenhoeklaan 9, Bilthoven, 3721 MA, The Netherlands.
30Department
of Gastroenterology and Hepatology, University Medical Centre,
Heidelberglaan 100, Utrecht, 3584 CX, The Netherlands.
31Julius Center for
Health Sciences and Primary Care, University Medical Center, Heidelberglaan
100, Utrecht, 3508 GA, The Netherlands.
32Department of Epidemiology and
Biostatistics, School of Public Health, Faculty of Medicine, Imperial College,
London, South Kensington Campus, London SW7 2AZ, UK.
33Institute of
Community Medicine, University of Tromsø, MH Building, Tromsø, 9037,
Norway.
34School of Clinical Medicine, University of Cambridge, The Old
Schools, Trinity Lane, CB2 1TN, UK.
35Medical Research Council, Epidemiology
Unit, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0QQ, UK.
36Cancer
Epidemiology Unit, University of Oxford, Richard Doll Building, Oxford, OX3
7LF, UK.
37Nutritional Epidemiology Group, Section of Nutrition and
Metabolism, International Agency for Research on Cancer (IARC), 150 Cours
Albert Thomas, Lyon, 69372, France.
38Department of Genomics of Common
Disease, School of Public Health, Imperial College London, South Kensington
Campus, London SW7 2AZ, UK.
Authors’ contributions
RR, AL, LD and RK contributed to the conception of the current analysis and
all authors were involved in the design and acquisition of data from the
EPIC cohort. RR, AL, LD and RK contributed to the analysis and all authors
contributed to the interpretation of the data. RR, AL and RK drafted the
manuscript and all authors revised the final draft critically for important
critical content. All authors have given final approval of the version to be
published.
Competing interests
The authors declare that they have no competing interests.
Received: 20 December 2011 Revised: 12 March 2012
Accepted: 14 May 2012 Published: 14 May 2012
References
1. Weigelt B, Reis-Filho JS: Histological and molecular types of breast
cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 2009, 6:718-730.
2. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP,
Sherman ME: Etiology of hormone receptor-defined breast cancer: a
systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004,
13:1558-1568.
3. Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI,
Lee AH, Robertson JF, Ellis IO: Biologic and clinical characteristics of
breast cancer with single hormone receptor positive phenotype. J Clin
Oncol 2007, 25:4772-4778.
4. Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, Rees CA, Pollack JR,
Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C,
Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular
portraits of human breast tumours. Nature 2000, 406:747-752.
5. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B,
Desmedt C, Ignatiadis M, Sengstag T, Schutz F, Goldstein DR, Piccart M,
Delorenzi M: Meta-analysis of gene expression profiles in breast cancer:
toward a unified understanding of breast cancer subtyping and
prognosis signatures. Breast Cancer Res 2008, 10:R65.
6. Suzuki R, Orsini N, Saji S, Key TJ, Wolk A: Body weight and incidence of
breast cancer defined by estrogen and progesterone receptor status–a
meta-analysis. Int J Cancer 2009, 124:698-712.
7. Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, Henderson BE:
Breast cancer risk factors defined by estrogen and progesterone
receptor status: the multiethnic cohort study. Am J Epidemiol 2009,
169:1251-1259.
8. Cotterchio M, Kreiger N, Theis B, Sloan M, Bahl S: Hormonal factors and
the risk of breast cancer according to estrogen- and progesterone-
receptor subgroup. Cancer Epidemiol Biomarkers Prev 2003, 12:1053-1060.
9. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE: Risk factors
for breast cancer according to estrogen and progesterone receptor
status. J Natl Cancer Inst 2004, 96:218-228.
10. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH,
Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-
Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE,
Yasmeen S, Prentice RL: Estrogen plus progestin and breast cancer
incidence and mortality in postmenopausal women. JAMA 2010,
304:1684-1692.
11. Breast cancer and hormone replacement therapy: collaborative
reanalysis of data from 51 epidemiological studies of 52,705 women
with breast cancer and 108,411 women without breast cancer.
Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997,
350:1047-1059.
12. Feigelson HS, Jonas CR, Teras LR, Thun MJ, Calle EE: Weight gain, body
mass index, hormone replacement therapy, and postmenopausal breast
cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev
2004, 13:220-224.
13. Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, Lopez AM,
Manson J, Margolis KL, Muti PC, Stefanick ML, McTiernan A: Obesity, body
size, and risk of postmenopausal breast cancer: the Women’s Health
Initiative (United States). Cancer Causes Control 2002, 13:741-751.
14. Lahmann PH, Hoffmann K, Allen N, van Gils CH, Khaw KT, Tehard B,
Berrino F, Tjonneland A, Bigaard J, Olsen A, Overvad K, Clavel-Chapelon F,
Nagel G, Boeing H, Trichopoulos D, Economou G, Bellos G, Palli D,
Tumino R, Panico S, Sacerdote C, Krogh V, Peeters PH, Bueno-de-
Mesquita HB, Lund E, Ardanaz E, Amiano P, Pera G, Quiros JR, Martinez C,
et al: Body size and breast cancer risk: findings from the European
Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer
2004, 111:762-771.
15. Riboli E, Kaaks R: The EPIC Project: rationale and study design. European
Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 1997,
26(Suppl 1):S6-14.
16. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, Charrondiere UR,
Hemon B, Casagrande C, Vignat J, Overvad K, Tjonneland A, Clavel-
Ritte et al. Breast Cancer Research 2012, 14:R76
http://breast-cancer-research.com/content/14/3/R76
Page 12 of 14Chapelon F, Thiebaut A, Wahrendorf J, Boeing H, Trichopoulos D,
Trichopoulou A, Vineis P, Palli D, Bueno-de-Mesquita HB, Peeters PH,
Lund E, Engeset D, Gonzalez CA, Barricarte A, Berglund G, Hallmans G,
Day NE, Key TJ, et al: European Prospective Investigation into Cancer and
Nutrition (EPIC): study populations and data collection. Public Health Nutr
2002, 5:1113-1124.
17. Haftenberger M, Lahmann PH, Panico S, Gonzalez CA, Seidell JC, Boeing H,
Giurdanella MC, Krogh V, Bueno-de-Mesquita HB, Peeters PH, Skeie G,
Hjartaker A, Rodriguez M, Quiros JR, Berglund G, Janlert U, Khaw KT,
Spencer EA, Overvad K, Tjonneland A, Clavel-Chapelon F, Tehard B,
Miller AB, Klipstein-Grobusch K, Benetou V, Kiriazi G, Riboli E, Slimani N:
Overweight, obesity and fat distribution in 50- to 64-year-old
participants in the European Prospective Investigation into Cancer and
Nutrition (EPIC). Public Health Nutr 2002, 5:1147-1162.
18. Spencer EA, Appleby PN, Davey GK, Key TJ: Validity of self-reported height
and weight in 4808 EPIC-Oxford participants. Public Health Nutr 2002,
5:561-565.
19. Bakken K, Fournier A, Lund E, Waaseth M, Dumeaux V, Clavel-Chapelon F,
Fabre A, Hemon B, Rinaldi S, Chajes V, Slimani N, Allen NE, Reeves GK,
Bingham S, Khaw KT, Olsen A, Tjonneland A, Rodriguez L, Sanchez MJ,
Etxezarreta PA, Ardanaz E, Tormo MJ, Peeters PH, van Gils CH, Steffen A,
Schulz M, Chang-Claude J, Kaaks R, Tumino R, Gallo V, et al: Menopausal
hormone therapy and breast cancer risk: impact of different treatments.
The European Prospective Investigation into Cancer and Nutrition. Int J
Cancer 2011, 128:144-156.
20. Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by
immunohistochemistry is superior to the ligand-binding assay for
predicting response to adjuvant endocrine therapy in breast cancer. J
Clin Oncol 1999, 17:1474-1481.
21. McCann J: Better assays needed for hormone receptor status, experts
say. J Natl Cancer Inst 2001, 93:579-580.
22. Layfield LJ, Gupta D, Mooney EE: Assessment of Tissue Estrogen and
Progesterone Receptor Levels: A Survey of Current Practice, Techniques,
and Quantitation Methods. Breast J 2000, 6:189-196.
23. Flowers JL, Burton GV, Cox EB, McCarty KS, Dent GA, Geisinger KR,
McCarty KS Jr: Use of monoclonal antiestrogen receptor antibody to
evaluate estrogen receptor content in fine needle aspiration breast
biopsies. Ann Surg 1986, 203:250-254.
24. Remmele W, Stegner HE: [Recommendation for uniform definition of an
immunoreactive score (IRS) for immunohistochemical estrogen receptor
detection (ER-ICA) in breast cancer tissue]. Pathologe 1987, 8:138-140.
25. Li CI, Malone KE, Daling JR: Interactions between body mass index and
hormone therapy and postmenopausal breast cancer risk (United
States). Cancer Causes Control 2006, 17:695-703.
26. Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, Day NE:
Validity and repeatability of a simple index derived from the short
physical activity questionnaire used in the European Prospective
Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr
2003, 6:407-413.
27. Lunn M, McNeil D: Applying Cox regression to competing risks. Biometrics
1995, 51:524-532.
28. Altman DG, De Stavola BL, Love SB, Stepniewska KA: Review of survival
analyses published in cancer journals. Br J Cancer 1995, 72:511-518.
29. Tarone RE, Chu KC: The greater impact of menopause on ER- than ER+
breast cancer incidence: a possible explanation (United States). Cancer
Causes Control 2002, 13:7-14.
30. Yasui Y, Potter JD: The shape of age-incidence curves of female breast
cancer by hormone-receptor status. Cancer Causes Control 1999,
10:431-437.
31. Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW: Frequency
distributions of breast cancer characteristics classified by estrogen
receptor and progesterone receptor status for eight racial/ethnic groups.
Cancer 2001, 92:37-45.
32. Dunnwald LK, Rossing MA, Li CI: Hormone receptor status, tumor
characteristics, and prognosis: a prospective cohort of breast cancer
patients. Breast Cancer Res 2007, 9:R6.
33. Anderson WF, Chatterjee N, Ershler WB, Brawley OW: Estrogen receptor
breast cancer phenotypes in the Surveillance, Epidemiology, and End
Results database. Breast Cancer Res Treat 2002, 76:27-36.
34. Dietel M, Lewis MA, Shapiro S: Hormone replacement therapy:
pathobiological aspects of hormone-sensitive cancers in women
relevant to epidemiological studies on HRT: a mini-review. Hum Reprod
2005, 20:2052-2060.
35. Allred DC, Brown P, Medina D: The origins of estrogen receptor alpha-
positive and estrogen receptor alpha-negative human breast cancer.
Breast Cancer Res 2004, 6:240-245.
36. Jordan VC: The ups and downs of the estrogen receptor. J Clin Oncol
2003, 21:3-4.
37. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER,
Yasuda H, Smyth GK, Martin TJ, Lindeman GJ, Visvader JE: Control of
mammary stem cell function by steroid hormone signalling. Nature 2010,
465:798-802.
38. Harris HR, Willett WC, Terry KL, Michels KB: Body fat distribution and risk
of premenopausal breast cancer in the Nurses’ Health Study II. J Natl
Cancer Inst 2011, 103:273-278.
39. Phipps AI, Chlebowski RT, Prentice R, McTiernan A, Stefanick ML, Wactawski-
Wende J, Kuller LH, ms-Campbell LL, Lane D, Vitolins M, Kabat GC,
Rohan TE, Li CI: Body size, physical activity, and risk of triple-negative
and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers
Prev 2011, 20:454-463.
40. John EM, Sangaramoorthy M, Phipps AI, Koo J, Horn-Ross PL: Adult body
size, hormone receptor status, and premenopausal breast cancer risk in
a multiethnic population: the San Francisco Bay Area breast cancer
study. Am J Epidemiol 2011, 173:201-216.
41. Hankinson SE: Endogenous hormones and risk of breast cancer in
postmenopausal women. Breast Dis 2005, 24:3-15.
42. Key TJ, Allen NE, Verkasalo PK, Banks E: Energy balance and cancer: the
role of sex hormones. Proc Nutr Soc 2001, 60:81-89.
43. Rose DP, Vona-Davis L: Interaction between menopausal status and
obesity in affecting breast cancer risk. Maturitas 2010, 66:33-38.
44. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL,
Dowsett M, Hankinson SE: Endogenous steroid hormone concentrations
and risk of breast cancer among premenopausal women. J Natl Cancer
Inst 2006, 98:1406-1415.
45. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P,
Bingham S, Boeing H, Bueno de Mesquita HB, Chang-Claude J, Clavel-
Chapelon F, Fournier A, van Gils CH, Gonzalez CA, Gurrea AB, Critselis E,
Khaw KT, Krogh V, Lahmann PH, Nagel G, Olsen A, Onland-Moret NC,
Overvad K, Palli D, Panico S, Peeters P, Quiros JR, Roddam A, et al: Serum
sex steroids in premenopausal women and breast cancer risk within the
European Prospective Investigation into Cancer and Nutrition (EPIC). J
Natl Cancer Inst 2005, 97:755-765.
46. Rosenberg LU, Einarsdottir K, Friman EI, Wedren S, Dickman PW, Hall P,
Magnusson C: Risk factors for hormone receptor-defined breast cancer in
postmenopausal women. Cancer Epidemiol Biomarkers Prev 2006,
15:2482-2488.
47. Beral V, Reeves G, Bull D, Green J: Breast cancer risk in relation to the
interval between menopause and starting hormone therapy. J Natl
Cancer Inst 2011, 103:296-305.
48. Fournier A, Fabre A, Mesrine S, Boutron-Ruault MC, Berrino F, Clavel-
Chapelon F: Use of different postmenopausal hormone therapies and
risk of histology- and hormone receptor-defined invasive breast cancer.
J Clin Oncol 2008, 26:1260-1268.
49. Tjonneland A, Christensen J, Thomsen BL, Olsen A, Overvad K, Ewertz M,
Mellemkjaer L: Hormone replacement therapy in relation to breast
carcinoma incidence rate ratios: a prospective Danish cohort study.
Cancer 2004, 100:2328-2337.
50. Chen WY, Hankinson SE, Schnitt SJ, Rosner BA, Holmes MD, Colditz GA:
Association of hormone replacement therapy to estrogen and
progesterone receptor status in invasive breast carcinoma. Cancer 2004,
101:1490-1500.
51. Saxena T, Lee E, Henderson KD, Clarke CA, West D, Marshall SF, Deapen D,
Bernstein L, Ursin G: Menopausal hormone therapy and subsequent risk
of specific invasive breast cancer subtypes in the California Teachers
Study. Cancer Epidemiol Biomarkers Prev 2010, 19:2366-2378.
52. Magne N, Toillon RA, Castadot P, Ramaioli A, Namer M: Different clinical
impact of estradiol receptor determination according to the analytical
method: A study on 1940 breast cancer patients over a period of 16
consecutive years. Breast Cancer Res Treat 2006, 95:179-184.
53. Chebil G, Bendahl PO, Idvall I, Ferno M: Comparison of
immunohistochemical and biochemical assay of steroid receptors in
Ritte et al. Breast Cancer Research 2012, 14:R76
http://breast-cancer-research.com/content/14/3/R76
Page 13 of 14primary breast cancer - clinical associations and reasons for
discrepancies. Acta Oncol 2003, 42:719-725.
54. Welsh AW, Moeder CB, Kumar S, Gershkovich P, Alarid ET, Harigopal M,
Haffty BG, Rimm DL: Standardization of estrogen receptor measurement
in breast cancer suggests false-negative results are a function of
threshold intensity rather than percentage of positive cells. J Clin Oncol
2011, 29:2978-2984.
55. Hede K: Breast cancer testing scandal shines spotlight on black box of
clinical laboratory testing. J Natl Cancer Inst 2008, 100:836-7, 844.
56. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S,
Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R,
Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A,
Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P,
Viale G, Visscher D, Wheeler T, Williams RB, et al: American Society of
Clinical Oncology/College Of American Pathologists guideline
recommendations for immunohistochemical testing of estrogen and
progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795.
57. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ:
Thresholds for therapies: highlights of the St Gallen International Expert
Consensus on the primary therapy of early breast cancer 2009. Ann
Oncol 2009, 20:1319-1329.
doi:10.1186/bcr3186
Cite this article as: Ritte et al.: Adiposity, hormone replacement therapy
use and breast cancer risk by age and hormone receptor status: a large
prospective cohort study. Breast Cancer Research 2012 14:R76.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Ritte et al. Breast Cancer Research 2012, 14:R76
http://breast-cancer-research.com/content/14/3/R76
Page 14 of 14